Cellectar Biosciences, Inc.

What they do

Cellectar develops drugs for cancer using its proprietary phospholipid ether drug conjugate (PDC) platform, designed to target cancer cells and limit off-target effects. Its three lead programs are iopofosine I 131 (beta-emitting iodine-131), CLR 121125 (Auger-emitting iodine-125), and CLR 121225 (alpha-emitting actinium-225). The company is primarily focused on radioconjugate PDCs (PRCs) for targeted delivery of radioisotopes to cancer cells.

Revenue drivers

• Iopofosine I 131 — Lead program targeting relapsed/refractory Waldenström macroglobulinemia (r/r WM); has Breakthrough Therapy Designation and is planned for NDA submission under accelerated approval. No commercial revenue yet.
• CLR 121125 (CLR 125) — Iodine-125 Auger-emitting program in Phase 1b dose-finding study for triple-negative breast cancer; preclinical data show activity in solid tumor models.
• CLR 121225 (CLR 225) — Actinium-225 alpha-emitting program with preclinical activity in pancreatic, colorectal, and breast cancer models; not yet in clinical trials.

Recent performance

For the quarter ended June 30, 2026, the company reported cash and equivalents of $34.0 million and total assets of $36.6 million, with shareholder equity of $29.9 million. Net income for 2025 was -$21.8 million, a narrowing from -$44.6 million in 2024. Operating cash flow for 2025 was -$23.1 million. The company has not generated revenue from product sales.

Strategy

Management is advancing iopofosine I 131 toward a confirmatory Phase 3 trial and a planned NDA submission in mid-2027 under the FDA's Accelerated Approval Program. They initiated site activation for the Phase 3 study and plan to dose the first patient in early 2027. The company is also progressing CLR 125 in a Phase 1b trial and continuing development of CLR 225. They plan to develop PDCs both independently and through research collaborations.

Risks

• No commercial revenue — The company has no approved products and relies on future regulatory approvals to generate revenue.
• Dependence on clinical trial success — All programs are in clinical or preclinical stages; failure to demonstrate safety and efficacy could halt development.
• Need for additional funding — Further development of iopofosine I 131 requires sufficient additional funding to initiate and at least partially enroll confirmatory studies.
• Regulatory uncertainty — Accelerated approval and conditional marketing authorization are not guaranteed; the FDA and EMA decisions are subject to review of clinical data.

Outlook

Management plans to submit a New Drug Application for iopofosine I 131 in mid-2027 under the FDA's Accelerated Approval Program, with an anticipated ~6-month review. They expect to open Phase 3 sites in the coming months and dose the first patient in early 2027, with full enrollment projected within 18-24 months of first patient. The company also anticipates multiple data and development milestones in the second half of 2026.